Phase II, multicenter, randomised, double-blind, placebo-controlled, p
Phase II, multicenter, randomised, double-blind, placebo-controlled, parallel group, dose-ranging study to determine the effect on MRI lesions and safety of RO0506997 in Relapsing Multiple Sclerosis
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- RO0506997
What it measured
Main measures
The primary endpoint is the cumulative number MRI enhancing lesions. Other endpoints are the cumulative number of active MRI lesions and the proportion of active MRIs. Clinical endpoints are the rate of MS attacks and change of MS status on the EDSS scale.
Disability progressionRelapsesMRI lesions
Who could take part
Relapsing MS
Show the full criteria
Inclusion criteria
Inclusion: Protocol section 4.1.1: MS-related Inclusion Criteria Exclusion: Protocol section 4.1.2: MS-related Exclusion Criteria
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To determine the effect of RO0506997 on MS by assessing the number of new
Loading reviews and guidelines…
History
- Status changed from Ongoing to Status unknown
- Result signal changed from Ongoing to Status unknown
Started
Feb 2005